Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Intravenous Iron Drugs Market size was over USD 3.8 billion in 2024 and is estimated to reach USD 10.8 billion by the end of 2037, expanding at a CAGR of 9.1% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of intravenous iron drugs is evaluated at USD 4.1 billion.
The enlarging patient pool of chronic kidney disease (CKD), malnutrition, and hematology disorders is propelling the intravenous iron drugs market. According to the projections, released by Kidney Research UK, in June 2023, over 13.0% of the global population was affected with CKD, which is predicted to become the 5th leading reason behind fatalities worldwide by 2040. The frequent coincidence of anemia among CKD patients is thriving for long and faster-acting solutions. A 2023 NLM study concluded that the average prevalence of anemia, the primary cause being erythropoietin or iron deficiency, in these residents is 15.4%, which rises with the disease progression. Thus, the rising incidences around the world are driving demand for this merchandise.
The rising economic burden of treating such conditions due to additional costs of iron deficiency anemia (IDA) is pushing regional public health associations to take immediate action. The advanced solutions from the intravenous iron drugs market are serving this purpose with better drug delivery systems and increased availability. However, the payers’ pricing for treatment may vary depending on regional accessibility, taxation policies, and used reagents. In this regard, an ISPOR Europe 2022 survey, backed by CSL Vifor, was conducted on the cost-effectiveness and availability of intravenous (IV) commodities for inflammatory bowel disease (IBD) patients, with complications resulting from IDA. The study aimed to develop an understanding of the current market needs and trends.
Comparative presentation of cost per patient for IV treatments in Sweden (2021)
|
Region |
FCM (in USD) |
FD (in USD) |
IS (in USD) |
|
Stockholm (incl. Gotland)
|
2378.6 |
2405.2 |
12199.9 |
|
JÖK (Jönköping, Östergötland, and Kalmar County) |
2381.4 |
2392.0 |
12162.5 |
|
3-Klöver (Örebro, Sörmland, and Värmland) |
2390.4 |
2413.0 |
12224.5 |
|
4-Klövern (Uppsala, Västmanland, Dalarna and Gävleborg) |
2376.9 |
2407.7 |
12199.3 |
Source: ISPOR Europe 2022 Survey
The above tabulation presents an evaluation of the cost per patient for ferric carboxymaltose (FCM), ferric derisomaltose (FD), and iron sucrose (IS) in selected areas of Sweden.
The report also classified the pricing of each 100mg IV vial by 2.0 ml, 1.0 ml, and 5.0 ml dosage in these regions as follows:
Payers’ pricing for IV supplements in Sweden (2021)
|
Region |
FCM 2.0 ml (USD) |
FD 1.0 ml (USD) |
IS 5.0 ml (USD) |
|
Stockholm |
12.3 |
11.7 |
3.6 |
|
JÖK |
12.8 |
12.5 |
3.6 |
|
3-Klöver |
13.1 |
12.5 |
3.5 |
|
4-Klövern |
12.3 |
13.0 |
3.6 |
Source: ISPOR Europe 2022 Survey
Intravenous Iron Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Improvement in administration and formulation: Innovations in pharmaceuticals are revolutionizing the approach toward patient safety and elongated action, bolstering the intravenous iron drugs market. Advanced profiling and properties of new formulations such as ferric carboxymaltose and isomaltoside are designed to deliver better disease management and reduced adverse reactions. For instance, in August 2024, Pharmacosmos commenced a large-scale clinical study in the U.S. to showcase the excellent safety profile and ability to improve outcomes of Monofer for attaining FDA approval. Such efforts of commercialization are strengthening consumer trust and provoking escalated adoption.
- Financial and regulatory support from authorities: Accelerated allowances and continuous funding are fueling growth in the intravenous iron drugs market. As more academic and government bodies show interest in deeper exploration, the diversity in this field increases. For instance, in November 2022, a USD 6.0 million fund from the National Institute of Health (NIH) was allocated to run a study on over 5,000 female candidates from Bangladesh, India, Pakistan, the Democratic Republic of Congo, Kenya, Zambia, and Guatemala. This grant helped researchers accelerate their work to find a suitable IV iron therapy, adhering to women with anemia after pregnancy. Such initiatives help the market leaders garner a progressive pace and wider consumer base.
Challenges
- Economic barriers among producers and consumers: Usually, the products from the intravenous iron drugs market are expensive. This often becomes a hurdle for individuals with constrained budgets, creating an unavoidable issue of unaffordability. On the other hand, preparing a formula that fits every criterion of quality standards while maintaining suitable pricing may become difficult to achieve due to volatility in raw materials supply and heightened R&D costs. Moreover, the additional expenses of acquiring compliance, specific ingredients, and appropriate delivery systems may pose a hurdle in global expansion.
- Disparities in availability and awareness: Complete penetration of the new treatment approaches from the intravenous iron drugs market may present a challenge in lack of knowledge. Rural areas from developed countries and a majority portion of low- and middle-income nations are still unaware of such advanced treatment methods, restricting widespread use. In addition, these regions suffer from the absence of adequate healthcare infrastructure, which limits accessibility. The predominant captivity of oral and other less invasive alternatives across the globe is also shrinking the marketplace for this sector.
Intravenous Iron Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
14% |
|
Base Year Market Size (2024) |
USD 7 billion |
|
Forecast Year Market Size (2037) |
USD 33.7 billion |
|
Regional Scope |
|
Intravenous Iron Drugs Segmentation
Product (Iron Sucrose, Iron Dextran, Ferric Carboxymaltose)
Carboxymaltose segment is projected to hold more than 50.2% intravenous iron drugs market share by 2037. Despite being an expensive option, the efforts from the healthcare authorities to implement payment incentives and adequate reimbursement coverages resulted in maximum adoption in this segment. Many clinical studies have proven FCM to be a safer and faster-acting option, in comparison to others. For instance, in June 2022, an NLM review of the capabilities of this sub-type in treating IDA in India displayed 97.5% and 97.2% very good to good ratings for efficacy and safety in 1800 participants. This established a strong profile of FCM, showcasing its efficacy in a shorter period, as soon as 4 weeks. The segment is also boosted by the previous shortage of iron sucrose and iron dextran.
Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Others)
In terms of application, the chronic kidney disease segment is projected to dominate the intravenous iron drugs market throughout the assessed period. The higher tendency of developing these associated conditions among CKD residents is the major reason behind the segment’s proprietary. Thus, the enlarging volume of affected individuals is the direct evidence of this fact. As per Research Nester, the chronic kidney disease industry is poised to register a value of USD 45.6 billion by 2037, where the drugs segment is supposed to hold the largest share of 45.0%. This signifies the potential of therapies to treat associated health issues, such as IDA, in generating lucrative revenues. Furthermore, increasing investments to improve access to care is contributing to this segment.
Our in-depth analysis of the global intravenous iron drugs market includes the following segments:
|
Product |
|
|
Application |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportIntravenous Iron Drugs Industry - Regional Synopsis
North America Market Analysis
North America intravenous iron drugs market is likely to capture revenue share of over 53.4% by 2037. The current scenario of growing IDA & CKD incidences is evolving this region as an attractive landscape for both domestic and international leaders. The 2023 CDC statistics revealed that approximately 35.5 million people in the U.S. were diagnosed with this condition, among whom 34.0% were aged 65 and over. On the same note, the Research Nester report states that the medical industry in North America, originating this illness, is poised to capture the highest share of 42.0% by 2037. These figures concludes the significance of this region in global revenue.
The intravenous iron drugs market in the U.S. is witnessing remarkable influence from the rising cases of heart failure (HF) and well-established healthcare infrastructure. According to the JACC Journals, 6.2 million adult individuals in this country encountered HF in 2022 and it is further predicted to register a 46% increment from 2012 to 2030. These depicted an economic burden of USD 30.7 billion. With such demographics, the country is dragging the focus of global leaders. For instance, in July 2021, Sandoz announced the commercial launch of a solely developed intravenous medicine, Ferumoxytol, in the U.S., enriching the generic accessibility of IDA curatives.
Canada is levitating the reach of the intravenous iron drugs market by improving outpatient services across its territory. Additionally, the accepting practice of the government and regulatory framework encourages them to engage their resources. For instance, in March 2024, CSL Vifor gained authorization for marketing Ferinject (ferric carboxymaltose) in Canada for adult HF habitats and 1-year and older pediatric residents with iron deficiency. This allowance allowed the company to leverage its reach toward the targeted consumer base, encompassing females in the reproductive stage and younger the generation. This represents a pre-established environment, benefitting newcomers in this field.
APAC Market Statistics
Asia Pacific is anticipated to register the fastest growth in the intravenous iron drugs market over the forecasted timeframe. The region’s emergence is also majorly depicted by the epidemiology of CKD and HF. The low- and middle-income countries (LMICs) in APAC are suffering the consequences, including iron deficiency anemia, of delayed intervention in these medical disciplines. According to a study published in PLOS, in February 2022, the overall commonness of end-stage (3-5) chronic kidney disorders in Asia accounted for 11.2%. As per the diverse economic classification, the same aspect accounted to be 13.8% in LMICs within the region. The statistics are drafting a thrive in this field for upcoming years.
India, with the continued government-issued capital influx and enlarging patient pool, is becoming a lucrative investment opportunity for pioneers in the intravenous iron drugs market. The collective effect of public and private campaigns is resulting in increased awareness among potential investors and participants, magnifying engagement in this sector. The country is also promoting domestic production to reduce reliance on foreign forces, creating golden opportunities for local leaders. For instance, in May 2023, Emcure Pharmaceuticals extended its parenteral iron portfolio by launching Orofer FCM 750, effective for almost all citizens. These creations are inspiring other competitors to foster a dedicated pipeline for this landscape.
China is cultivating resources from the intravenous iron drugs market to serve the emphasizing demand for affordable yet effective therapeutics. The country is well-adaptive to the latest advancements in this field, which makes it a premium business hub for medicine developers. In addition, the favorable regulatory framework is allowing foreign giants to take wider leap toward extending their merchandise in this broadened marketplace. For instance, in November 2022, CSL Vifor attained the marketing allowance for Ferinject from the National Medical Products Administration (NMPA) in China, in collaboration with Fresenius Kabi. Such local support helps this nation grab more international attention.
Companies Dominating the Intravenous Iron Drugs Landscape
- Allergan Plc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AMAG Pharmaceuticals, Inc.
- Luitpold Pharmaceuticals, Inc.
- American Regent, Inc.
- Pharmacosmos A/S
- Sanofi US
- Vifor Pharma Ltd.
- Cadila Pharmaceuticals
Key players in the intravenous iron drugs market are setting their targets in bigger marketplaces, emerging from low- and middle-income countries such as India, Africa, China, Malaysia, the Philippines, and Thailand. This is testified by the recent foreign investments and international collaborations in these nations. For instance, in June 2024, Menarini partnered with Pharmacosmos to acquire the marketing, sales, and distribution rights for MonoFer (ferric derisomaltose) in Singapore and Malaysia. Based on the previous success in Australia, the company grabbed the deal of commercializing this product across APAC. Such beneficial collaborations are also involving other global developers to bring innovative IV preparations, diversifying the field. These key players in intravenous iron drugs market:
In the News
- In August 2024, Pharmacosmos announced the merger of G1 Therapeutics against a transaction of USD 405.0 million to empower its resources and expertise in hematology. The acquisition also helped the company leverage the distribution and commercialization of Monoferric (ferric derisomaltose) 500mg/5ml Injection.
- In March 2024, Cadila Pharmaceuticals introduced a ground-breaking iron injection, Redshot FCM, to treat both adult and pediatric patients aged 1 and over with iron deficiency anemia. The next-generation ferric carboxymallose formulation features exceptional tolerability and minimal to zero risk of anaphylaxis.
Author Credits: Radhika Pawar
- Report ID: 7224
- Published Date: Feb 25, 2025
- Report Format: PDF, PPT
